Numerai GP LLC Purchases 16,457 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Numerai GP LLC raised its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 46.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,696 shares of the company’s stock after acquiring an additional 16,457 shares during the quarter. Numerai GP LLC’s holdings in Neumora Therapeutics were worth $548,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC bought a new position in Neumora Therapeutics in the fourth quarter valued at about $281,000. Graham Capital Management L.P. bought a new position in Neumora Therapeutics in the fourth quarter valued at about $707,000. Deutsche Bank AG lifted its holdings in Neumora Therapeutics by 50.4% in the fourth quarter. Deutsche Bank AG now owns 73,103 shares of the company’s stock valued at $775,000 after acquiring an additional 24,483 shares during the period. Cutter Capital Management LP bought a new position in Neumora Therapeutics in the fourth quarter valued at about $1,590,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Neumora Therapeutics in the fourth quarter worth about $854,000. Institutional investors own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. William Blair cut Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday. Guggenheim cut Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, March 7th. HC Wainwright reduced their price target on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus cut Neumora Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.29.

Neumora Therapeutics Trading Down 9.5%

NASDAQ:NMRA opened at $0.62 on Thursday. Neumora Therapeutics, Inc. has a 12-month low of $0.61 and a 12-month high of $17.19. The stock has a 50-day moving average price of $0.88 and a 200 day moving average price of $4.50. The stock has a market capitalization of $99.49 million, a P/E ratio of -0.33 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). On average, research analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.